I started where most scientists do — fascinated by how living systems work and determined to understand them properly. A BSc at Aberystwyth and then research degrees at Warwick took me deep into molecular and synthetic biology, where I learned the discipline that still underpins everything I do: respect for what the data actually says, and suspicion of the story we'd like it to tell.
But the lab was only ever half the story. I became increasingly drawn to the harder question of how frontier science becomes something real — a product, a company, a thing that outlives the grant. That pull led me to co-found and lead NanoSyrinx, a venture built around intracellular protein delivery, where I've had to learn the parts of company-building they don't teach you at the bench: raising money, hiring ahead of certainty, and making decisions with incomplete information and real consequences.
Along the way I've spent meaningful time on the other side of the table — close to how investors evaluate deep tech, what makes them lean in, and what quietly kills a round. That perspective changed how I think about building. It's one thing to know your science is good; it's another to make it legible and fundable to people who decide in twenty minutes what took you twenty months.
Zephyr Venturecraft is how I bring all of that to other founders and teams. My centre of gravity is therapeutics development — it's where my depth runs and where I add the most — but good company-building instincts travel, so I'm always open to the wider deep-tech problems that share the same DNA. I'm not a generalist consultant who happens to like science, and I'm not an academic dispensing theory. I'm someone who has carried the weight of the things I now advise on — and that's the only kind of advice I think is worth paying for.